CAMBRIDGE, Mass., Dec. 2, 2014 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing novel nucleic acid therapeutics for cancer and rare diseases, today announced that Company management will present at the 26th Annual Piper Jaffray Healthcare Conference on Wednesday, December 3, 2014 at 3:30 p.m. EST in New York.
A live audio webcast of the presentation will be available in the Investors and Media section of Idera's website at http://www.iderapharma.com or at the link http://www.media-server.com/m/p/kkrv2ds7. An archived version will also be available on the Company's website after the event for 90 days.
About Idera Pharmaceuticals
Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic approach for the treatment of genetically defined forms of B-cell lymphoma and rare autoimmune diseases. Idera's proprietary technology involves creating novel nucleic acid therapeutics designed to inhibit over-activation of Toll-like Receptors (TLRs). In addition to its TLR programs, Idera is developing gene silencing oligonucleotides (GSOs) that it has created using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA. To learn more about Idera, visit www.iderapharma.com.
CONTACT: Investor and Media Contact: Jim Baker Executive Director, Corporate Affairs 617-679-5516 email@example.com